SEC Form 4 · accession 0001179110-19-001942
CATABASIS PHARMACEUTICALS INC · CATB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew John Nichols
Officer — Chief Scientific Officer
Period of report
Feb 13, 2019
Accepted (ET)
Feb 15, 2019 · 8:41 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001454789
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.39 | Feb 13, 2019 | A | 40,000 | A | — | Feb 12, 2029 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1This option was granted on February 13, 2019 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 13, 2019 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.